Heads up reconstructive microsurgery: Utilisation of the three-dimensional microscope in microvascular procedures
A Sleiwah1, P Mohanna1, Ho AsJoe M1
1Department of Plastic Surgery, Guy's and St Thomas' NHS Foundation Trust, London, UK.
Journal of Plastic, Reconstructive & Aesthetic Surgery : JPRAS
|November 30, 2021
Summary
Three-dimensional (3D) microscopes enhance ergonomics and surgeon comfort in reconstructive microsurgery without impacting clinical outcomes. This innovation offers improved staff engagement and teaching experiences for microsurgeons.
Area of Science:
- Microsurgery and Surgical Technology
- Medical Device Innovation
- Occupational Health in Surgery
Background:
- Microscope technology has evolved to improve surgical ergonomics, resolution, and visual field.
- Three-dimensional (3D) microscopes represent a significant advancement, though their adoption in UK reconstructive microsurgery is limited.
- Reconstructive microsurgeons face occupational risks due to prolonged microscope use, necessitating ergonomic improvements.
Discussion:
- This study compared 3D microscopes against traditional microscopes in a matched cohort of reconstructive microsurgery patients.
- Surgeons completed a survey to evaluate their experience with both types of microscopes.
- Patient matching was based on age, comorbidities, and oncologic procedures to ensure comparable groups.
Key Insights:
- No significant differences were observed in operative time, ischemia time, or post-operative complications between the 3D and traditional microscope groups.
- Surgeons reported enhanced ergonomics, improved posture, and increased staff engagement with 3D microscopes.
- The 3D microscope facilitated a better teaching experience for surgical staff.
Outlook:
- 3D microscopes offer significant ergonomic benefits for reconstructive microsurgeons, potentially mitigating work-related musculoskeletal conditions.
- Wider adoption of 3D microscopy in reconstructive microsurgery could improve surgeon well-being and training.
- Further research with larger cohorts is warranted to confirm long-term clinical benefits and cost-effectiveness.


